Publicaciones en colaboración con investigadores/as de Dokuz Eylül University (22)

2023

  1. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

    Neurodegenerative Disease Management, Vol. 13, Núm. 4, pp. 215-221

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  4. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

    Multiple Sclerosis Journal, Vol. 29, Núm. 2, pp. 221-235

  5. Diminishing benefits of urban living for children and adolescents’ growth and development

    Nature, Vol. 615, Núm. 7954, pp. 874-883

  6. Stoma-free survival after anastomotic leak following rectal cancer resection: worldwide cohort of 2470 patients

    British Journal of Surgery, Vol. 110, Núm. 12, pp. 1863-1876

  7. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

2021

  1. Determinants of therapeutic lag in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 12, pp. 1838-1851

  2. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

  3. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  4. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

  5. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

  2. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

2019

  1. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468

  2. Rising rural body-mass index is the main driver of the global obesity epidemic in adults

    Nature

2017

  1. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults

    The Lancet, Vol. 390, Núm. 10113, pp. 2627-2642